Memantine may affect pseudobulbar affect in patients with Alzheimer's disease

Acta Neuropsychiatrica

Volumn 25, Issue 6, 2013, Pages 361-366

  Prokšelj, Tatjana ^a   Jerin, Aleš ^b   Kogoj, Aleš ^c  

^a General Hospital Novo mesto   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^c UNIVERSITY PSYCHIATRIC HOSPITAL   (Slovenia)

Author keywords

Affective symptoms; Aggression; Emotional disturbances; Memantine; Serotonin

Indexed keywords

CITALOPRAM; MEMANTINE; SEROTONIN;

AGED; AGGRESSION; AGITATION; ALZHEIMER DISEASE; ARTICLE; CASE REPORT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; EMOTION; FEMALE; HUMAN; IRRITABILITY; MALE; MOOD DISORDER; NEUROPSYCHIATRIC INVENTORY SCORE; OVERT AGGRESSION SCALE MODIFIED SCORE; PATHOLOGICAL CRYING; PATHOLOGICAL LAUGHTER; PSEUDOBULBAR AFFECT; SCORING SYSTEM; SEROTONINERGIC TRANSMISSION;

EID: 84889839271     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1017/neu.2013.14     Document Type: Article

References (36)

1. CUMMINGS JL, COLE G. Alzheimer disease. JAMA 2002;287: 2335-2338.
2. MEGA MS, CUMMINGS JL, FIORELLO T, GORNBEIN J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996;46:130-135.
3. CUMMINGS JL, ARCINIEGAS DB, BROOKS BR et al. Defining and diagnosing involuntary emotional expression disorder. CNS Spectr 2006;11:1-7.
4. LIEBERMAN A, BENSON F. Control of emotional expression in pseudobulbar palsy. Arch Neurol 1977;34:717-719.
5. TANAKA M, SUMITSUJI N. Electromyographic study of facial expression during pathological laughing and crying. Electromyogr Clin Neurophysiol 1991;31:399-406.
6. STARKSTEIN SE, MIGLIORELLI R, TESÓN A et al. Prevalence and clinical correlates of pathological affective display in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1995; 59:55-60.
7. SELKOE DJ. The molecular pathology of Alzheimer's disease. Neuron 1991;6:487-498.
8. LANCTÔT KL, HERRMANN N, MAZZOTTA P. Role of serotonin in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci 2001;13:5-21.
9. CAMACHO A, DIMSDALE JE. Platelets and psychiatry: lessons learned from old and new studies. Psychosom Med 2000;62:326-336.
10. MESZAROS Z, BORSICZKY D, MATE M et al. Platelet MAO-B activity and serotonin content in patients with dementia: effect of age, medication and disease. Neurochem Res 1998; 23:863-868.
11. KUMAR AM, SEVUSH S, KUMAR M, RUIZ J, EISDORFER C. Peripheral serotonin in Alzheimer's disease. Neuropsychobiology 1995;32:9-12.
12. MIMICA N, MUCK-SELER D, PIVAC N, MUSTAPIC M, FOLNEGOVIC-SMALC V. Platelet serotonin and monoamine oxidase activity in patients with early-onset and lateonset of Alzheimer's disease. Period Biol 2005;107: 211-215.
13. MIMICA N, MUCK-ŠELER D, PIVAC N et al. Platelet serotonin and monoamine oxidase in Alzheimer's disease with psychotic features. Coll Antropol 2008;32:119-122.
14. SIDDIQUE H, HYNAN LS, WEINER MF. Effect of a serotonin reuptake inhibitor on irritability, apathy and psychotic symptoms in patients with Alzheimer's disease. J Clin Psychiatry 2009;70:915-918.
15. ANDERSEN G, VESTERGAARD K, RIIS JO. Citalopram for poststroke pathological crying. Lancet 1993;342:837-839.
16. PARSONS CG, DANYSZ W, QUACK G. Memantine is clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 1999;38:735-767.
17. VAN DYKE CH, TARIOT PN, MEYERS B, MALCA RESNICK E. A 24-week randomized controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 2007;21:136-143.
18. GAUTHIER S, LOFT H, CUMMINGS J. Improvement in behavioral symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry 2008;23:537-545.
19. BROOKS BR, THIRSTED RA, APPEL SH et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology 2004;63:1364-1370.
20. PANITCH HS, THISTED RA, SMITH RA et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol 2006;59:780-787.
21. TORELLA FC, PELLICANO M, BOWERY NG. Dextromethorphan and neuromodulation: old drug coughs up new activities. Trends Pharmacol Sci 1989;10:501-507.
22. ROGAWSKI MA. Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents toward an understanding of their favorable tolerability. Amino Acids 2000;19:133-149.
23. AMERICAN PSYCHIATRIC ASSOCIATION. Diagnostic and statistical manual of mental disorders, 4th edition. Washington, DC: American Psychiatric Association, 2000.
24. MCKHANN G, DRACHMAN D, FOLSTEIN M, KATZMAN R, PRICE D, STADLAN EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health & Human Services Task Force on Alzheimer's disease. Neurology 1984;34: 939-944.
25. ROBINSON RG, PARIKH RM, LIPSLEY JR, STARKSTEIN SE, PRICE TR. Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. Am J Psychiatry 1993;150:286-293.
26. CUMMINGS JL, MEGA M, GRAY K, ROSENBERG-TOMPSON S, CARUSI DA, GORNBEIN J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
27. COCCARO EF, HARVEY PD, KUPSAW-LAWRENCE E, HERBERT JL, BERNSTEIN DP. Development of Neuropharmacologically based behavioral assessments of impulsive aggressive behaviour. J Neuropsych Clin Neurosci 1991;3:S44-S51.
28. RAKUSA M, GRANDA G, KOGOJ A, MLAKAR J, VODUSEK DB. Mini-mental state examination: standardization and validation for the elderly Slovenian population. Eur J Neurol 2006;13:141-145.
29. RAMMES G, RUPPRECHT R, FERRARI U, ZIEGLGÄNSBERGER W, PARSONS CG. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkylcyclohexanes antagonize 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a noncompetitive manner. Neurosci Lett 2001;306:81-84.
30. ONOGI H, ISHIGAKI S, NAKAGAWASAI O et al. Influence of memantine on brain monoaminergic neurotransmission parameters in mice: neurochemical and behavioral study. Biol Pharm Bull 2009;32:850-855.
31. MUHONEN LH, LÖNNQVIST J, JUVA K, ALHO H. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry 2008;69:392-399.
32. BERMACK JE, DEBONNEL G. The role of sigma receptors in depression. J Pharmacol Sci 2005;97:317-336.
33. STAHL SM. Stahl's essential psychopharmacology: neuroscientific basis and practical applications. New York: Cambridge University Press, 2008.
34. NARITA N, HASHIMOTO K, TOMITAKA S, MINABE Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 1996;307:117-119.
35. VAN WATUM PJ. Rapid response to low dose citalopram in pathological crying. Gen Hosp Psychiatry 2001;23:166-170.
36. KING RR, REISS JP. Treatment of pseudobulbar affect with citalopram in a patient with progressive multifocal leukoencephalopathy. J Clin Neurosci 2012;19:185-186.